ANTIINFLAMMATORY ACTIVITY;
ARTERIAL PRESSURE;
BLOOD PRESSURE MONITORING;
CARDIOVASCULAR DISEASE;
CLINICAL FEATURE;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG EFFECT;
DRUG EFFICACY;
DRUG HALF LIFE;
DRUG INDUSTRY;
DRUG PROGRAM;
DRUG SAFETY;
DRUG SCREENING;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
GASTRODUODENAL ULCER;
GASTROINTESTINAL DISEASE;
GASTROINTESTINAL TOXICITY;
HUMAN;
IN VITRO STUDY;
KNEE OSTEOARTHRITIS;
LICENSING;
MEDICAL DECISION MAKING;
MUCOSAL DISEASE;
NONHUMAN;
PRIORITY JOURNAL;
REVIEW;
RHEUMATOID ARTHRITIS;
TISSUE PERFUSION;
ANIMALS;
CLINICAL TRIALS, PHASE II;
CLINICAL TRIALS, PHASE II AS TOPIC;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DOUBLE-BLIND METHOD;
DRUG EVALUATION, PRECLINICAL;
HUMANS;
NAPROXEN;
NITRIC OXIDE;
PLACEBOS;
RANDOMIZED CONTROLLED TRIALS;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RHEUMATIC DISEASES;
Anti-inflammatory potency and gastrointestinal toxicity of a new compound, nitronaproxen
Jan
Cuzzolin L, Conforti A, Adami A. Anti-inflammatory potency and gastrointestinal toxicity of a new compound, nitronaproxen. Pharmacological Research 31: 61-65, Jan 1995
NicOx SA. NicOx Completes Enrolment of Phase 3 Trial for HCT 3012 in Osteoarthritis Ahead of Schedule. Media Release: 24 May 2006. Available from URL: http://www.nicox.com
NicOx SA. NicOx Initiates New Trial to Establish HCT 3012 as Osteoarthritis Treatment With Beneficial Blood Pressure Profile. Media Release: 4 May 2006. Available from URL: http://www.nicox.com
NicOx SA. NicOx Announces Initiation of Phase 3 Trial For HCT 3012 in Osteoarthritis. Media Release: 20 Dec 2005. Available from URL: http://www.nicox.com
Nicox. NicOx Announces Positive Evaluation of Overall Phase II Clinical Results on AZD3582 by a U.S. Consultant Advisory Board. Media Release: 27 Jan 2004. Available from URL: http://www.nicox.com
NicOx. NicOx Initiates Clinical Study to Evaluate HCT 3012 Effects on Blood Pressure Vs. Rofecoxib. Media Release: 8 Sep 2004. Available from URL: http://www.nicox.com
A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis
Mar
Lohmander LS, McKeith D, Svensson O, et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Annals of the Rheumatic Diseases 64: 449-456, No. 3, Mar 2005
A phase II study of the efficacy and safety of AZD3582, a cinod, in subjects with osteoarthritis of the knee
Jul
Schnitzer TJ, Kivitz AJ, Lipetz RS, et al. A phase II study of the efficacy and safety of AZD3582, a cinod, in subjects with osteoarthritis of the knee. Annals of the Rheumatic Diseases 63 (Suppl. 1): 62-63, Jul 2004
NicOx SA. NicOx Announces Preliminary Review of Data from Phase II Study of AZD3582. Media Release: 11 Mar 2003. Available from URL: http://www.nicox.com
Pharmacokinetics of AZD3582, a COX-inhibiting nitric oxide donator, in animals suggest potential clinical utility as an analgesic drug
Fagerholm U, Andersson L, Swedmark S, et al. Pharmacokinetics of AZD3582, a COX-inhibiting nitric oxide donator, in animals suggest potential clinical utility as an analgesic drug. Pharmacologist 44 (Suppl. 1): 171, 2002
AZD3582, a CINOD, differs significantly from rofecoxib in having a neutral effect on blood pressure in patients with osteoarthritis: Results of a randomized, controlled trial
Sep
Schnitzer T, Ballabio M, Bonizzoni E. AZD3582, a CINOD, differs significantly from rofecoxib in having a neutral effect on blood pressure in patients with osteoarthritis: results of a randomized, controlled trial. Arthritis and Rheumatism 50 (Suppl.): 347, No. 9, Sep 2004
NO-naproxen modulates inflammation pain and T cell response in rat Freund's adjuvant arthritis
Cirino G, Calignano A, Iannaro A. NO-naproxen modulates inflammation pain and T cell response in rat Freund's adjuvant arthritis. Mediators of Inflammation 8 (Suppl. 1): 59, 1999
